Skip to main content
. Author manuscript; available in PMC: 2009 Sep 3.
Published in final edited form as: Cell Cycle. 2009 Jun 1;8(11):1794–1802. doi: 10.4161/cc.8.11.8738

Figure 4.

Figure 4

Roscovitine protects from lethal acute GvHD in vivo. Lethally irradiated (1,000 cGy) B6D2F1 mice (H-2b/d) underwent transplantation with either bone marrow alone (BM) (n = 5) or with bone marrow and splenocytes from parental B6 (H-2b) mice, as described in Materials and Methods. Mice that received bone marrow and splenocytes (n = 11 to 15 per group) were subsequently treated with vehicle (BMT) or with roscovitine (BMT + R) on the day of transplantation and daily thereafter for a total of three weeks. Survival (A) was monitored after transplantation and significantly delayed mortality of lethal acute GvHD was observed in roscovitine treated mice (BMT + R) compared with control-treated mice (BMT) (p = 0.001). (B) Serum was obtained on day 7 after transplantation and concentration of TNFα was determined by ELISA. Results are expressed as mean value from 3–7 mice in each group ± standard deviation.